Cardiac fibrosis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Angiotensin II stimulates cardiac fibrosis and conduction heterogeneity.
|
19648063 |
2009 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II) plays an important role on the pathogenesis of cardiac fibrosis.
|
29322373 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II), an effective component of renin-angiotensin system, plays a pivotal role in cardiac fibrosis, which may further contribute to heart failure.
|
30369577 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (AngII) has been implicated in the development of cardiac fibrosis.
|
31640463 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease.
|
20157054 |
2010 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD44 Deficiency in Mice Protects the Heart Against Angiotensin Ii-Induced Cardiac Fibrosis.
|
29470359 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Echocardiographic analysis, Sirius Red staining and immunofluorescence staining were performed to investigate the function of circHIPK3 in angiotensin II (Ang II) induced cardiac fibrosis in vivo.
|
30967276 |
2019 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.
|
29081650 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous Insl6 protein inhibits cardiac systolic dysfunction and cardiac fibrosis in angiotensin II- and isoproterenol-induced cardiac stress models.
|
29887522 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.
|
30670148 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-to-mesenchymal transition (EndMT) is a mechanism that promotes cardiac fibrosis induced by Angiotensin II (AngII).
|
29073623 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
29030734 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glaucocalyxin A attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts.
|
30072098 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the use a highly selective TG2 small-molecule inhibitor to test the efficacy of TG2 inhibition as an anti-fibrotic therapy for heart failure employing two different in vivo models of cardiac fibrosis: Progressively induced interstitial cardiac fibrosis by pressure overload using angiotensin II infusion: Acutely induced focal cardiac fibrosis through myocardial infarction by ligation of the left anterior descending coronary artery (AMI model).
|
29795262 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the potential anti-myocardial fibrosis effect and mechanism of SalB on Angiotensin II (Ang II)-induced cardiac fibrosis in vitro.
|
30365482 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we found that A77 1726 treatment attenuated pressure overload or angiotensin II (Ang II)-induced cardiac hypertrophy <i>in vivo</i>, as well as agonist-induced hypertrophic response of cardiomyocytes <i>in vitro</i> In addition, we showed that A77 1726 administration prevented induction of cardiac fibrosis by inhibiting cardiac fibroblast (CF) transformation into myofibroblast.
|
29540538 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-29b plays a protective role in AngII-mediated cardiac remodeling and may be a therapeutic agent for cardiac fibrosis by targeting the TGF-β/Smad3 pathway.
|
24569834 |
2014 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
28474247 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling.
|
28944921 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice in which αv integrin is depleted in PDGFRβ<sup>+</sup> cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.
|
29061963 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we investigated the effects of lncRNA FAF on angiotensinogen II (Ang II)-induced cardiac fibrosis in neonatal rat CFs and explored the mechanism underlying these effects.
|
31708099 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Opposite Effects of Moderate and Extreme Cx43 Deficiency in Conditional Cx43-Deficient Mice on Angiotensin II-Induced Cardiac Fibrosis.
|
31652649 |
2019 |
Cardiac fibrosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis.
|
25898844 |
2015 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protocatechuic acid attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts through inhibiting the NOX4/ROS/p38 signaling pathway.
|
31318113 |
2019 |